Trade Legend Biotech Corporation - LEGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 34.18 |
| Open | 33.67 |
| 1-Year Change | -46.37% |
| Day's Range | 33.67 - 34.42 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 34.21 | 0.38 | 1.12% | 33.83 | 34.43 | 33.41 |
| Apr 24, 2025 | 34.18 | 0.18 | 0.53% | 34.00 | 34.36 | 33.56 |
| Apr 23, 2025 | 34.26 | -0.41 | -1.18% | 34.67 | 35.11 | 33.94 |
| Apr 22, 2025 | 34.42 | 1.96 | 6.04% | 32.46 | 34.44 | 32.46 |
| Apr 21, 2025 | 32.19 | 0.03 | 0.09% | 32.16 | 32.88 | 31.96 |
| Apr 17, 2025 | 32.71 | -0.09 | -0.27% | 32.80 | 33.02 | 31.69 |
| Apr 16, 2025 | 33.40 | 0.17 | 0.51% | 33.23 | 33.50 | 32.31 |
| Apr 15, 2025 | 33.67 | 0.32 | 0.96% | 33.35 | 34.93 | 33.05 |
| Apr 14, 2025 | 32.04 | -0.51 | -1.57% | 32.55 | 32.80 | 31.74 |
| Apr 11, 2025 | 31.93 | 1.01 | 3.27% | 30.92 | 32.43 | 30.92 |
| Apr 10, 2025 | 31.22 | 0.12 | 0.39% | 31.10 | 32.67 | 30.70 |
| Apr 9, 2025 | 32.01 | 2.26 | 7.60% | 29.75 | 32.72 | 29.20 |
| Apr 8, 2025 | 30.67 | -0.49 | -1.57% | 31.16 | 31.48 | 30.11 |
| Apr 7, 2025 | 30.15 | -0.01 | -0.03% | 30.16 | 31.56 | 29.22 |
| Apr 4, 2025 | 31.93 | 0.38 | 1.20% | 31.55 | 32.22 | 30.83 |
| Apr 3, 2025 | 32.79 | 0.20 | 0.61% | 32.59 | 33.39 | 32.34 |
| Apr 2, 2025 | 33.17 | 1.87 | 5.97% | 31.30 | 33.46 | 31.08 |
| Apr 1, 2025 | 31.47 | -2.58 | -7.58% | 34.05 | 34.20 | 31.34 |
| Mar 31, 2025 | 33.87 | -0.15 | -0.44% | 34.02 | 34.29 | 32.79 |
| Mar 28, 2025 | 34.99 | -0.35 | -0.99% | 35.34 | 35.49 | 34.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com